Sinkovics J G
Postgrad Med. 1976 Feb;59(2):110-5. doi: 10.1080/00325481.1976.11714273.
Immunotherapy of human tumors is a promising new modality that remains highly investigational and poses unforeseen risks. It should preferably be conducted in patients brought into remission by conventional antitumor therapy and against the background of a complex, reliable monitoring system capable of quantitatively measuring the patient's antitumor immune reactions.
人类肿瘤的免疫疗法是一种有前景的新方法,但仍处于高度研究阶段且存在不可预见的风险。它最好在通过传统抗肿瘤疗法实现缓解的患者中进行,并在一个能够定量测量患者抗肿瘤免疫反应的复杂、可靠的监测系统背景下开展。